-DOCSTART-	O

Title	O
:	O
Galantamine	B-I
in	O
the	O
treatment	O
of	O
cognitive	O
decline	O
in	O
patients	B-P
with	I-P
vascular	I-P
dementia	I-P
or	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
with	I-P
cerebrovascular	I-P
disease	I-P
.	O

METHODS	O
:	O
A	O
post	O
hoc	O
sub	O
-	O
analysis	O
of	O
a	O
6	O
-	O
month	O
,	O
multicentre	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
and	O
a	O
subsequent	O
6	O
-	O
month	O
,	O
open	O
-	O
label	O
extension	O
.	O

Patients	B-P
diagnosed	I-P
with	I-P
probable	I-P
vascular	I-P
dementia	I-P
or	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
with	I-P
cerebrovascular	I-P
disease	I-P
were	O
treated	O
with	O
galantamine	B-I
(	I-I
Reminyl	I-I
)	I-I
24	O
mg	O
/	O
day	O
for	O
12	O
months	O
(	O
6	O
months	O
double	O
-	O
blind	O
and	O
6	O
months	O
open	O
-	O
label	O
)	O
or	O
placebo	B-C
for	O
6	O
months	O
(	O
double	O
-	O
blind	O
)	O
followed	O
by	O
galantamine	B-I
24	O
mg	O
/	O
day	O
for	O
6	O
months	O
(	O
open	O
-	O
label	O
)	O
.	O

Changes	O
in	O
scores	O
on	O
the	B-O
11	I-O
-	I-O
item	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
/	I-O
11	I-O
)	I-O
were	O
assessed	O
at	O
months	O
6	O
,	O
7	O
.	O
5	O
and	O
12	O
.	O

Mean	O
changes	O
from	O
baseline	O
were	O
analysed	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Clinical	O
study	O
on	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
from	O
the	O
viewpoint	O
of	O
Xin	O
and	O
Shen	O
]	O
.	O

METHODS	O
:	O
Sixty	B-P
patients	I-P
with	I-P
AD	I-P
were	O
divided	O
into	O
3	O
groups	O
according	O
to	O
their	O
MMSE	O
and	O
ADL	O
scores	O
before	O
treatment	O
,	O
using	O
randomized	O
block	O
design	O
.	O

They	O
were	O
treated	O
separately	O
with	O
TXR	B-I
,	O
BSR	B-I
and	O
Donepezil	B-I
(	I-I
Dp	I-I
)	I-I
for	O
12	O
weeks	O
.	O

The	O
changes	O
of	O
MMSE	B-O
score	I-O
,	O
ADL	B-O
score	I-O
,	O
neuro	B-O
-	I-O
psychology	I-O
amount	I-O
table	I-O
score	I-O
,	O
including	O
FOM	B-O
,	O
RVR	B-O
,	O
DS	B-O
and	O
BD	B-O
,	O
as	O
well	O
as	O
the	B-O
overall	I-O
operational	I-O
evaluation	I-O
before	O
and	O
after	O
treatment	O
were	O
analyzed	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
the	O
effects	O
of	O
donepezil	B-I
on	O
neuronal	O
markers	O
and	O
hippocampal	O
volumes	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
pilot	O
study	O
,	O
67	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
received	O
24	O
weeks	O
of	O
treatment	O
with	O
donepezil	B-I
(	O
5	O
mg	O
/	O
day	O
for	O
the	O
first	O
28	O
days	O
and	O
10	O
mg	O
/	O
day	O
thereafter	O
)	O
or	O
placebo	B-C
.	O

Patients	O
were	O
reevaluated	O
at	O
6	O
-	O
week	O
intervals	O
to	O
measure	O
change	O
from	O
baseline	O
in	O
several	O
outcome	O
measures	O
,	O
including	O
right	B-O
,	O
left	B-O
,	O
and	O
total	B-O
hippocampal	I-O
volumes	I-O
,	O
measured	O
with	O
magnetic	B-O
resonance	I-O
imaging	I-O
;	O
brain	B-O
concentrations	I-O
of	I-O
N	I-O
-	I-O
acetylaspartate	I-O
,	O
measured	O
with	O
proton	B-O
magnetic	I-O
resonance	I-O
spectroscopy	I-O
;	O
and	O
cognition	B-O
,	O
assessed	O
with	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
cognitive	I-O
subscale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Metal	O
-	O
protein	O
attenuation	O
with	O
iodochlorhydroxyquin	B-I
(	I-I
clioquinol	I-I
)	I-I
targeting	O
Abeta	O
amyloid	O
deposition	O
and	O
toxicity	O
in	O
Alzheimer	O
disease	O
:	O
a	O
pilot	O
phase	O
2	O
clinical	O
trial	O
.	O

METHODS	O
:	O
A	O
pilot	O
phase	O
2	O
clinical	O
trial	O
in	O
patients	B-P
with	I-P
moderately	I-P
severe	I-P
Alzheimer	I-P
disease	I-P
.	O

-DOCSTART-	O

Title	O
:	O
The	O
efficacy	O
of	O
donepezil	B-I
in	O
the	O
treatment	O
of	O
neuropsychiatric	O
symptoms	O
in	O
Alzheimer	O
disease	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
with	I-P
marked	I-P
neuropsychiatric	I-P
symptoms	I-P
at	I-P
baseline	I-P
(	I-P
Neuropsychiatric	I-P
Inventory	I-P
[	I-P
NPI	I-P
]	I-P
>	I-P
11	I-P
points	I-P
)	I-P
were	O
treated	O
openly	O
with	O
donepezil	O
5	O
mg	O
daily	O
for	O
6	O
weeks	O
followed	O
by	O
10	O
mg	O
daily	O
for	O
a	O
further	O
6	O
weeks	O
.	O

Patients	O
were	O
then	O
randomized	O
(	O
60	O
:	O
40	O
)	O
to	O
either	O
placebo	B-C
or	O
10	B-I
mg	I-I
donepezil	I-I
daily	O
.	O

All	O
patients	O
were	O
assessed	O
at	O
6	O
weeks	O
and	O
provided	O
there	O
was	O
no	O
marked	O
cognitive	O
deterioration	O
their	O
blinded	O
treatment	O
was	O
continued	O
for	O
a	O
further	O
6	O
weeks	O
.	O

NPI	B-O
and	O
carer	B-O
distress	I-O
were	O
assessed	O
at	O
6	O
weekly	O
intervals	O
throughout	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
open	O
-	O
label	O
,	O
comparative	O
study	O
of	O
rivastigmine	B-I
,	O
donepezil	B-I
and	O
galantamine	B-I
in	O
a	O
real	O
-	O
world	O
setting	O
.	O

METHODS	O
:	O
Outcome	O
measures	O
included	O
the	B-O
MiniMental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
the	B-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
)	I-O
,	O
Instrumental	B-O
Activity	I-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
IADL	I-O
)	I-O
and	O
ADL	B-O
scales	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
donepezil	B-I
in	O
early	O
-	O
stage	O
Alzheimer	O
disease	O
:	O
a	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
24	O
-	O
week	O
,	O
placebo	O
-	O
controlled	O
study	O
that	O
enrolled	O
patients	B-P
with	I-P
early	I-P
-	I-P
stage	I-P
Alzheimer	I-P
disease	I-P
.	O

Patients	O
were	O
randomized	O
in	O
an	O
approximately	O
2	O
:	O
1	O
ratio	O
to	O
donepezil	B-I
,	O
5	O
mg	O
/	O
d	O
,	O
for	O
the	O
first	O
6	O
weeks	O
,	O
with	O
a	O
forced	O
escalation	O
to	O
10	O
mg	O
/	O
d	O
thereafter	O
(	O
n	O
=	O
96	O
)	O
,	O
or	O
placebo	B-C
(	O
n	O
=	O
57	O
)	O
.	O

The	O
primary	O
efficacy	O
measure	O
was	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
.	O

Secondary	O
efficacy	O
measures	O
included	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
the	B-O
Computerized	I-O
Memory	I-O
Battery	I-O
Test	I-O
,	O
the	B-O
Clinical	I-O
Dementia	I-O
Rating	I-O
Scale	I-O
-	I-O
Sum	I-O
of	I-O
the	I-O
Boxes	I-O
,	O
the	B-O
Patient	I-O
Global	I-O
Assessment	I-O
Scale	I-O
,	O
and	O
the	B-O
Apathy	I-O
Scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Vitamin	B-I
E	I-I
and	O
donepezil	B-I
for	O
the	O
treatment	O
of	O
mild	O
cognitive	O
impairment	O
.	O

METHODS	O
:	O
In	O
a	O
double	O
-	O
blind	O
study	O
,	O
we	O
evaluated	O
subjects	B-P
with	I-P
the	I-P
amnestic	I-P
subtype	I-P
of	I-P
mild	I-P
cognitive	I-P
impairment	I-P
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
receive	O
2000	B-I
IU	I-I
of	I-I
vitamin	I-I
E	I-I
daily	O
,	O
10	B-I
mg	I-I
of	I-I
donepezil	I-I
daily	O
,	O
or	O
placebo	B-C
for	O
three	O
years	O
.	O

The	O
primary	O
outcome	O
was	O
clinically	B-O
possible	I-O
or	O
probable	B-O
Alzheimer	I-O
'	I-O
s	I-O
disease	I-O
;	O
secondary	O
outcomes	O
were	O
cognition	B-O
and	O
function	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
effects	O
of	O
Abeta	B-I
immunization	I-I
(	I-I
AN1792	I-I
)	I-I
in	O
patients	B-P
with	I-P
AD	I-P
in	O
an	O
interrupted	O
trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
multicenter	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
trial	O
of	O
IM	B-I
AN1792	I-I
225	O
microg	O
plus	O
the	B-I
adjuvant	I-I
QS	I-I
-	I-I
21	I-I
50	O
microg	O
(	O
300	O
patients	O
)	O
and	O
saline	B-C
(	O
72	O
patients	O
)	O
included	O
patients	B-P
aged	I-P
50	I-P
to	I-P
85	I-P
years	I-P
with	I-P
probable	I-P
AD	I-P
,	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
15	I-P
to	I-P
26	I-P
.	O

Injections	O
were	O
planned	O
for	O
months	O
0	O
,	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
.	O

Safety	O
and	O
tolerability	O
were	O
evaluated	O
,	O
and	O
pilot	B-O
efficacy	I-O
(	O
AD	B-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
[	I-O
ADAS	I-O
-	I-O
Cog	I-O
]	I-O
,	O
MRI	B-O
,	O
neuropsychological	B-O
test	I-O
battery	I-O
[	I-O
NTB	I-O
]	I-O
,	O
CSF	B-O
tau	I-O
,	O
and	O
Abeta42	B-O
)	O
was	O
assessed	O
in	O
anti	O
-	O
AN1792	O
antibody	O
responder	O
patients	O
(	O
immunoglobulin	O
G	O
titer	O
>	O
or	O
=	O
1	O
:	O
2	O
,	O
200	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
cohort	O
study	O
of	O
effectiveness	O
of	O
acetylcholinesterase	B-I
inhibitors	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
From	O
September	O
2000	O
to	O
December	O
2001	O
,	O
a	B-P
total	I-P
of	I-P
5	I-P
,	I-P
462	I-P
patients	I-P
diagnosed	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
were	O
enrolled	O
at	O
the	O
time	O
of	O
their	O
first	O
prescription	O
of	O
the	O
study	O
drugs	O
and	O
followed	O
up	O
for	O
an	O
average	O
of	O
10	O
.	O
5	O
months	O
.	O

Responders	O
were	O
defined	O
as	O
patients	O
with	O
a	B-O
mini	I-O
-	I-O
mental	I-O
state	I-O
examination	I-O
(	I-O
MMSE	I-O
)	I-O
score	I-O
improvement	O
of	O
2	O
or	O
more	O
points	O
from	O
baseline	O
after	O
9	O
months	O
of	O
therapy	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
timed	B-I
bright	I-I
light	I-I
treatment	I-I
for	O
rest	O
-	O
activity	O
disruption	O
in	O
institutionalized	B-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
The	O
purpose	O
of	O
this	O
randomized	O
clinical	O
trial	O
was	O
to	O
test	O
the	O
effectiveness	O
of	O
timed	B-I
bright	I-I
light	I-I
therapy	I-I
in	O
reducing	O
rest	O
-	O
activity	O
(	O
circadian	O
)	O
disruption	O
in	O
institutionalized	B-P
patients	I-P
with	I-P
AD	I-P
.	O

The	O
experimental	O
groups	O
received	O
either	O
morning	B-I
(	I-I
9	I-I
.	I-I
30	I-I
-	I-I
10	I-I
.	I-I

30	I-I
am	I-I
)	I-I
or	O
afternoon	B-I
(	I-I
3	I-I
.	I-I
30	I-I
-	I-I
4	I-I
.	I-I

30	I-I
pm	I-I
)	I-I
bright	I-I
light	I-I
exposure	I-I
(	O
>	O
or	O
=	O
2500	O
lux	O
in	O
gaze	O
direction	O
)	O
Monday	O
through	O
Friday	O
for	O
10	O
weeks	O
.	O

The	O
control	O
group	O
received	O
usual	B-C
indoor	I-C
light	I-C
(	O
150	O
-	O
200	O
lux	O
)	O
.	O

Nighttime	B-O
sleep	I-O
,	O
daytime	B-O
wake	I-O
,	O
and	O
rest	B-O
-	I-O
activity	I-O
parameters	I-O
were	O
determined	O
by	O
actigraphy	B-O
.	O

Repeated	O
measures	O
analysis	O
of	O
variance	O
was	O
employed	O
to	O
test	O
the	O
primary	O
study	O
hypotheses	O
.	O

-DOCSTART-	O

Title	O
:	O
Brief	B-I
psychotherapy	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Individuals	O
were	O
randomised	O
to	O
receive	O
six	O
sessions	O
of	O
psychodynamic	B-I
interpersonal	I-I
therapy	I-I
or	O
treatment	B-C
as	I-C
usual	I-C
;	O
cognitive	B-O
function	I-O
,	O
activities	B-O
of	I-O
daily	I-O
living	I-O
,	O
a	B-O
global	I-O
measure	I-O
of	I-O
change	I-O
,	O
and	O
carer	B-O
stress	I-O
and	O
coping	B-O
were	O
assessed	O
prior	O
to	O
and	O
after	O
the	O
intervention	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
crossover	O
trial	O
of	O
high	B-I
-	I-I
carbohydrate	I-I
foods	I-I
in	O
nursing	B-P
home	I-P
residents	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
associations	O
among	O
intervention	O
response	O
,	O
body	O
mass	O
index	O
,	O
and	O
behavioral	O
and	O
cognitive	O
function	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
four	I-P
nursing	I-P
home	I-P
residents	I-P
with	I-P
probable	I-P
AD	I-P
who	I-P
ate	I-P
independently	I-P
participated	O
in	O
a	O
randomized	O
,	O
crossover	O
,	O
nonblinded	O
study	O
of	O
two	O
nutrition	O
interventions	O
.	O

The	O
intervention	O
described	O
here	O
included	O
replacing	O
12	O
nonconsecutive	O
"	O
traditional	O
"	O
dinners	O
with	O
meals	B-I
high	I-I
in	I-I
carbohydrate	I-I
but	O
comparable	O
to	O
traditional	B-C
dinners	I-C
in	O
protein	O
.	O

Measures	O
included	O
weighed	B-O
food	I-O
intake	I-O
,	O
body	B-O
weight	I-O
,	O
cognitive	B-O
function	I-O
(	O
as	O
assessed	O
using	O
the	B-O
Severe	I-O
Impairment	I-O
Battery	I-O
and	O
Global	B-O
Deterioration	I-O
Scale	I-O
)	O
,	O
behavioral	B-O
disturbances	I-O
(	O
as	O
assessed	O
using	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
-	I-O
Nursing	I-O
Home	I-O
Version	I-O
)	O
,	O
and	O
behavioral	B-O
function	I-O
(	O
as	O
assessed	O
using	O
the	B-O
London	I-O
Psychogeriatric	I-O
Rating	I-O
Scale	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
observation	O
and	O
mechanism	O
study	O
on	O
treatment	O
of	O
senile	O
dementia	O
with	O
Naohuandan	B-I
.	O

METHODS	O
:	O
Clinical	O
study	O
:	O
Fifty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
SD	I-P
,	I-P
whose	I-P
diagnosis	I-P
conforms	I-P
to	I-P
the	I-P
Diagnostic	I-P
Standard	I-P
of	I-P
DSM	I-P
-	I-P
IV	I-P
issued	I-P
by	I-P
American	I-P
Association	I-P
of	I-P
Psychiatry	I-P
,	O
were	O
enrolled	O
and	O
randomly	O
assigned	O
into	O
two	O
groups	O
.	O

The	O
30	O
patients	O
in	O
the	O
treated	O
group	O
were	O
treated	O
with	O
NHD	B-I
,	O
4	O
capsules	O
each	O
time	O
,	O
3	O
times	O
daily	O
.	O

The	O
28	O
patients	O
in	O
the	O
control	O
group	O
were	O
treated	O
with	O
Piracetam	B-C
,	O
1	O
.	O
6	O
g	O
each	O
time	O
,	O
3	O
times	O
daily	O
.	O

The	O
therapeutic	O
course	O
for	O
both	O
groups	O
was	O
3	O
months	O
.	O

The	O
therapeutic	O
efficacy	O
was	O
estimated	O
and	O
compared	O
by	O
comprehensive	B-O
scores	I-O
of	I-O
memory	I-O
and	O
cognition	B-O
,	O
scores	B-O
of	I-O
Mini	I-O
-	I-O
mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
and	O
Activities	B-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
ADL	I-O
)	I-O
.	O

Experimental	O
study	O
:	O
Rats	O
were	O
divided	O
into	O
the	O
control	O
group	O
,	O
the	O
model	O
group	O
and	O
the	B-I
high	I-I
-	I-I
dosage	I-I
and	O
low	B-I
-	I-I
dosage	I-I
NHD	I-I
treated	O
groups	O
.	O

The	O
protective	O
effect	O
of	O
NHD	B-I
on	O
the	O
per	O
-	O
oxidative	O
damage	O
of	O
hippocampal	O
neurons	O
in	O
beta	O
-	O
amyloid	O
protein	O
induced	O
SD	O
model	O
was	O
observed	O
and	O
the	O
related	O
criteria	O
were	O
determined	O
.	O

-DOCSTART-	O

Title	O
:	O
Risperidone	B-I
in	O
the	O
treatment	O
of	O
psychosis	O
of	O
Alzheimer	O
disease	O
:	O
results	O
from	O
a	O
prospective	O
clinical	O
trial	O
.	O

METHODS	O
:	O
The	O
authors	O
conducted	O
a	O
randomized	O
,	O
eight	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
trial	O
involving	O
nursing	B-P
home	I-P
residents	I-P
diagnosed	I-P
with	I-P
AD	I-P
and	I-P
psychosis	I-P
.	O

Four	B-P
hundred	I-P
seventy	I-P
-	I-P
three	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
placebo	B-C
(	O
N	O
=	O
238	O
)	O
or	O
1	B-I
.	I-I
0	I-I
to	I-I
1	I-I
.	I-I
5	I-I
mg	I-I
risperidone	I-I
per	O
day	O
(	O
N	O
=	O
235	O
)	O
.	O

Coprimary	O
efficacy	O
end	O
points	O
were	O
:	O
changes	O
in	O
scores	O
on	O
the	B-O
Behavioral	I-O
pathology	I-O
in	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
(	I-O
BEHAVE	I-O
-	I-O
AD	I-O
)	I-O
Psychosis	I-O
subscale	I-O
and	O
Clinical	B-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CGI	I-O
-	I-O
C	I-O
)	I-O
.	O

Protocol	O
-	O
specified	O
subgroup	O
analyses	O
were	O
performed	O
by	O
demographics	O
and	O
dementia	O
severity	O
.	O

